Key facts
- Haemonetics Corporation is updating its reportable segment structure.
- The change aims to align external financial reporting with operational management.
- The new structure will be effective for the first quarter of fiscal year 2027.
Haemonetics Corporation, a global medical technology company focused on improving patient outcomes through innovative solutions, announced an update to its reportable segment structure. This change is designed to enhance the alignment between the company's external financial reporting and its internal operational management framework. The revised segment structure will officially take effect starting from the first quarter of fiscal year 2027. This move is intended to provide a clearer and more accurate representation of the company's business performance and strategic focus to external stakeholders.